Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-11-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details board resolutions, amounts involved, counterparties, risk control measures, and compliance with regulatory requirements. The document is relatively short (2761 characters) and primarily serves as a progress update on the use of idle raised funds for cash management, not a full financial report or audit. It references previous announcements and regulatory filings but does not contain comprehensive financial statements or detailed financial analysis. This fits the description of a Capital/Financing Update (CAP), as it relates to the company's fundraising proceeds and their management, specifically the use of idle raised funds for cash management activities.
2024-11-06 Chinese
关于增资子公司Salubris Biotherapeutics, Inc.的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's plan to increase capital investment in its subsidiary Salubris Biotherapeutics, Inc. It details the investment amount, the ownership structure before and after the investment, the purpose of the investment, and the board's approval of the transaction. There are no financial statements or detailed financial performance data presented; rather, it is a disclosure about a capital increase transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is about 4772 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2024-10-21 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2024 年第三季度报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including revenue, net profit, earnings per share, asset and liability changes, cash flow statements, shareholder information, and notes on fundraising and investment projects. The report explicitly states it is a quarterly report (third quarter) and includes comprehensive financial statements and analysis. It is not a brief announcement or a certification but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-21 Chinese
第六届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the sixth board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the 2024 third quarter report and a capital increase in a subsidiary. The document is relatively short (1308 characters) and primarily serves as a public notice of board decisions rather than the full report itself. It references the 2024 third quarter report but does not contain the report's financial data or detailed analysis. It also includes an announcement of a capital increase in a subsidiary. Given the nature of the document as a board meeting resolution announcement and the approval of a quarterly report, it fits best under Board/Management Information (MANG) because it reports on board decisions and management actions. It is not the full quarterly report (IR), nor is it a simple announcement of report publication (RPA).
2024-10-21 Chinese
关于控股股东部分股份质押及解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, released, and the status of pledged shares. The document is relatively short (2248 characters) and focuses on share pledge activities, which are related to shareholding and capital structure but do not constitute a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about share pledges. The content fits best under the category of Share Issue/Capital Change (SHA), as it concerns changes in share pledges and releases affecting the company's capital structure.
2024-10-10 Chinese
关于质量回报双提升行动方案的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding their "Quality and Return Double Improvement" action plan. It discusses company strategy, innovation, financial performance highlights for the first half of 2024, shareholder returns including dividends and share repurchases, employee stock plans, investor relations, and corporate governance improvements. The document is a detailed corporate announcement focusing on strategic initiatives, financial results summary, and shareholder return policies. It does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is longer than a brief announcement but primarily serves as a corporate update and shareholder communication. It is not a regulatory filing, certification, or a report publication announcement. The content aligns best with a Capital/Financing Update (CAP) because it includes information on share repurchases and dividend policy, which are capital structure and financing related activities, alongside performance highlights and strategic plans. Therefore, the most appropriate classification is CAP with high confidence.
2024-08-30 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.